KR20010094519A - Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives - Google Patents

Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives Download PDF

Info

Publication number
KR20010094519A
KR20010094519A KR1020000016866A KR20000016866A KR20010094519A KR 20010094519 A KR20010094519 A KR 20010094519A KR 1020000016866 A KR1020000016866 A KR 1020000016866A KR 20000016866 A KR20000016866 A KR 20000016866A KR 20010094519 A KR20010094519 A KR 20010094519A
Authority
KR
South Korea
Prior art keywords
carbon atoms
methylthiophenyl
furanone
haloisobutyryl
compound
Prior art date
Application number
KR1020000016866A
Other languages
Korean (ko)
Inventor
이기화
최영훈
주영협
신송석
변영주
김진관
정신
Original Assignee
서경배
주식회사 태평양
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서경배, 주식회사 태평양 filed Critical 서경배
Priority to KR1020000016866A priority Critical patent/KR20010094519A/en
Priority to TR2001/02958T priority patent/TR200102958T2/en
Priority to BRPI0011172A priority patent/BRPI0011172B8/en
Priority to AT00921133T priority patent/ATE256672T1/en
Priority to NZ514101A priority patent/NZ514101A/en
Priority to PL351125A priority patent/PL204249B1/en
Priority to US09/744,762 priority patent/US6492416B1/en
Priority to SK1451-2001A priority patent/SK286314B6/en
Priority to CNB008062293A priority patent/CN1166658C/en
Priority to AU41480/00A priority patent/AU767811B2/en
Priority to EA200100958A priority patent/EA004432B1/en
Priority to DE60007267T priority patent/DE60007267T2/en
Priority to CA002369979A priority patent/CA2369979C/en
Priority to CZ20013662A priority patent/CZ300766B6/en
Priority to IL14530500A priority patent/IL145305A0/en
Priority to ES00921133T priority patent/ES2213007T3/en
Priority to KR1020017012902A priority patent/KR20010111584A/en
Priority to PCT/KR2000/000339 priority patent/WO2000061571A1/en
Priority to DZ003265A priority patent/DZ3265A1/en
Priority to HU0200623A priority patent/HU227863B1/en
Priority to PT00921133T priority patent/PT1109799E/en
Priority to JP2000610845A priority patent/JP3844657B2/en
Priority to EP00921133A priority patent/EP1109799B1/en
Priority to IL145305A priority patent/IL145305A/en
Priority to MA26357A priority patent/MA25406A1/en
Priority to NO20014986A priority patent/NO327814B1/en
Priority to MXPA01010312A priority patent/MXPA01010312A/en
Publication of KR20010094519A publication Critical patent/KR20010094519A/en
Priority to HK02108027.8A priority patent/HK1046413B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C1/00Chairs adapted for special purposes
    • A47C1/12Theatre, auditorium, or similar chairs
    • A47C1/13Indicators; Devices for reserving or the like
    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C7/00Parts, details, or accessories of chairs or stools
    • A47C7/62Accessories for chairs
    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C7/00Parts, details, or accessories of chairs or stools
    • A47C7/62Accessories for chairs
    • A47C7/72Adaptations for incorporating lamps, radio sets, bars, telephones, ventilation, heating or cooling arrangements or the like
    • A47C7/725Adaptations for incorporating lamps, radio sets, bars, telephones, ventilation, heating or cooling arrangements or the like for illumination, e.g. lamps
    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C7/00Parts, details, or accessories of chairs or stools
    • A47C7/62Accessories for chairs
    • A47C7/72Adaptations for incorporating lamps, radio sets, bars, telephones, ventilation, heating or cooling arrangements or the like
    • A47C7/727Adaptations for incorporating lamps, radio sets, bars, telephones, ventilation, heating or cooling arrangements or the like with speakers

Landscapes

  • Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: A process for producing 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives is provided, thereby the compounds, especially 4,5-diaryl-3(2H)-furanone derivatives can be produced in high yield. CONSTITUTION: The process for producing 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives of the formula(I) comprises of reacting the compound of formula(II) with 2-haloisobutyryl cyanide or 2-haloisobutyryl halide, if necessary, in the presence of an oxidizing agent, in which X is substituted or unsubstituted aryl or heteroaryl; Y is alkyl, cycloalkyl, substituted or unsubstituted aryl or heteroaryl; and the reaction is carried out in organic solvent in the presence of base, wherein base is sodium hydride, butyllithium, lithium t-butoxide, potassium t-butoxide, sodium t-butoxide, lithium diisopropyl amide, sodium bis(trimethylsillyl) amide, potassium bis(trimethylsillyl) amide, lithium bis(trimethylsillyl) amide or bromomagnesium diisopropyl amide.

Description

2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체의 제조 방법{Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives}Synthetic Method of 2,2,4,5-tetrasubstituted 3 (2H) -furanone derivatives}

본 발명은 2,2,4,5-사중 치환된 3(2H)-퓨라논[2,2,4,5-tetrasubstituted 3(2H)-furanone] 유도체를 제조하기 위한 새로운 방법에 관한 것이다.The invention 2,2,4,5- fourfold substituted 3 (2H) - it relates to a novel method for fabricating the fuser ranon [2,2,4,5-tetrasubstituted 3 (2H) -furanone] derivative.

3(2H)-퓨라논은 향미 성질, 세포 독성(cytotoxic), 그리고 항종양 작용을 가지고 있는 물질로서(Bioorg. Chem. 1977 , 6, 287;Tetrahedron 1983,39, 2241;J. Am. Chem. Soc. 1976,98, 2295;Bull. Chem. Soc. Jpn. 1983,56, 3088), 최근에는 3(2H)-퓨라논 중 2,2,4,5-사중 치환된 3(2H)-퓨라논, 특히 4,5-디아릴 3(2H)-퓨라논 유도체가 프로스타글란딘의 생합성 효소의 하나인 시클로옥시게네이즈-2 (cyclooxygenase-2)를 선택적으로 저해하는 작용이 있다는 것이 본 발명자들에 의해 밝혀졌다(대한민국특허 출원 99-13170호(1999년4월14일)).3 ( 2H ) -furanone is a substance with flavor, cytotoxic, and anti-tumor activity ( Bioorg. Chem. 1977 , 6 , 287; Tetrahedron 1983 , 39 , 2241; J. Am. Chem. ..... Soc 1976, 98, 2295; Bull Chem Soc Jpn 1983, 56, 3088), recently, 3 (2H) - 2,2,4,5- Pew fourfold substituted 3 (2H) of the ranon-Pugh The inventors have found that lanones, particularly 4,5-diaryl 3 ( 2H ) -furanone derivatives, have an effect of selectively inhibiting cyclooxygenase-2, one of prostaglandin's biosynthetic enzymes. (Korean Patent Application No. 99-13170 (14 April 1999)).

따라서, 이러한 생리활성이 있는 3(2H)-퓨라논에 대한 관심이 높아졌고, 그 제조 방법에 대한 연구도 많이 이루어졌다.Therefore, interest in 3 ( 2H ) -furanone having such physiological activity has been increased, and a lot of studies on the preparation method have been made.

종래, 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체들을 제조하기 위해서는 예를 들면, 4-하이드록시-2-알카인-1-온(4-hydroxy-2-alkyn-1-one)의 직렬 이산화탄소 부가-제거(tandem CO2addition-elimination)방법(Tetrahedron Lett.1988,29, 5941), 알레닉 케톤(allenic ketone)을 Hg(OAc)2를 이용하여 산화시키는 방법(Tetrahedron Lett. 1985,26, 703), 이소옥사졸린(isoxazoline)을 환원시킨 뒤, 산촉매하에서 고리화시키는 방법(Tetrahedron Lett.1983,24, 2079) 및 유기 금속 화합물을 γ,γ-이중 치환된 β-브로모-α,β-부테놀라이드(γ,γ-disubstituted β-bromo-α,β-butenolides)와 반응시킨 뒤, 산처리하는 방법(Tetrahedron Lett.1980,21, 4057)으로 2,2,5-삼중치환된 3(2H)-퓨라논 유도체들을 먼저 제조하고, 예를 들면, 팔라듐 금속을 이용하는 스즈키(Suzuki) 탄소-탄소 결합 공정(대한민국특허출원 제 99-13170호)을 거쳐야만 한다. 그러나, 이 방법은 많은 부생성물이 생성되기 때문에, 이를 위해 별도의 분리, 정제 공정을 거쳐야 하는 단점이 있다.Conventionally, for the preparation of 2,2,4,5-quad substituted 3 ( 2H ) -furanone derivatives, for example, 4-hydroxy-2-alkain-1-one (4-hydroxy-2-alkyn Tandem CO 2 addition-elimination method of -1-one) ( Tetrahedron Lett . 1988 , 29 , 5941), oxidative allele ketone using Hg (OAc) 2 ( Tetrahedron Lett. 1985 , 26 , 703), a method of reducing isoxazoline, followed by cyclization under an acid catalyst ( Tetrahedron Lett . 1983 , 24 , 2079) and γ, γ-double substituted β React with bromo-α, β-butenolide (γ, γ-disubstituted β-bromo-α, β-butenolides), followed by acid treatment ( Tetrahedron Lett . 1980 , 21 , 4057). , 5-Trisubstituted 3 ( 2H ) -furanone derivatives must first be prepared and subjected to, for example, a Suzuki carbon-carbon bonding process using Palladium metal (Korean Patent Application No. 99-13170). Should be. However, this method has a disadvantage in that a large number of by-products are produced, which requires a separate separation and purification process.

한편, 2,2,5-삼중 치환된 3(2H)-퓨라논 유도체를 경유하지 않고, 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체들을 직접 제조하는 방법으로는, γ-하이드록시-β-디카르보닐 화합물을 산촉매하에서 고리화시키는 방법(J. Am. Chem. Soc. 1981 , 103, 1501)과, 탄산칼슘 촉매하의 이산화탄소 분위기에서 4-하이드록시-2-알카인-1-온(4-hydroxy-2-alkyn-1-one)과 알킬할라이드를 반응시키는 방법(Synthesis 1996 ,1431)이 공지되어 있다. 그러나, 전자의 방법은 3-메틸-3-(트리메틸실록시)-2-부탄온(3-methyl-3-(trimethylsiloxy)-2-butanone)과 알데하이드를 알돌축합(aldol condensation)반응을 통하여 얻은 β-하이드록시케톤의 산화/고리화 반응으로 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체를 얻을 수는 있으나, 하기 화학식 2와 같은 화합물을 얻기가 용이하지 않기 때문에 다양한 4,5-디아릴-3(2H)-퓨라논 유도체를 제조하기 어려운 문제점이 있으며, 후자의 방법은 알킬할라이드를 사용하기 때문에 4- 및 5- 위치가 아릴기로 치환된 3(2H)-퓨라논 유도체를 제조할 수 없는 문제점이 있다.On the other hand, without the 2,2,5-trisubstituted 3 ( 2H ) -furanone derivative, a method for directly preparing 2,2,4,5-quad substituted 3 ( 2H ) -furanone derivatives , γ-hydroxy-β-dicarbonyl compound ( J. Am. Chem. Soc. 1981 , 103 , 1501) and 4-hydroxy-2-alkae in a carbon dioxide atmosphere under a calcium carbonate catalyst Methods of reacting phosphine-1-one (4-hydroxy-2-alkyn-1-one) with alkyl halides ( Synthesis 1996 , 1431) are known. However, the former method is obtained through the aldol condensation reaction of 3-methyl-3- (trimethylsiloxy) -2-butanone and aldehyde. It is possible to obtain 3 ( 2H ) -furanone derivatives substituted with 2,2,4,5-quadrate by oxidation / ring reaction of β-hydroxyketone, but it is not easy to obtain a compound represented by the following Chemical Formula 2 various 4,5-diaryl -3 (2H) - Pew ranon producing the derivative, and it is difficult, the latter method due to the use of alkyl halides 3 is 4-and 5-positions is substituted with an aryl group (2H) - There is a problem that can not prepare a furanone derivative.

상기 식에서,Where

Y는 페닐, 치환된 페닐기 등이다.Y is phenyl, substituted phenyl group and the like.

이에, 본 발명자들은 상기한 문제점을 해결할 수 있는 새로운 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체의 제조 방법에 대하여 연구를 거듭한 결과, 에탄온(ethanone) 유도체와 2-할로이소부티릴시아나이드(2-haloisobutyryl cyanide) 또는 2-할로이소부티릴할라이드(2-haloisobutyryl halide)와의 축합 및 고리화 반응에 의해 매우 높은 수율로 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체를 제조할 수 있음을 발견하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have conducted a study on a method for preparing a new 2,2,4,5-quad substituted 3 ( 2H ) -furanone derivative that can solve the above problems, and as a result, ethanone derivatives and 2,2,4,5-quadrate substitution in very high yields by condensation and cyclization with 2-haloisobutyryl cyanide or 2-haloisobutyryl halide It has been found that the prepared 3 ( 2H ) -furanone derivative can be prepared, thereby completing the present invention.

따라서, 본 발명의 목적은 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체를 고수율로 얻을 수 있는 새로운 제조 방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a novel process for obtaining 2,2,4,5-quaternary substituted 3 ( 2H ) -furanone derivatives in high yield.

상기한 목적을 달성하기 위하여, 본 발명에 따른 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체의 제조방법은,In order to achieve the above object, a method for preparing a 2,2,4,5-quarried substituted 3 ( 2H ) -furanone derivative according to the present invention,

하기 일반식 (Ⅱ) 화합물을 2-할로이소부티릴시아나이드 또는 2-할로이소부티릴할라이드와 반응시켜 하기 일반식 (Ⅰ)의 2,2,4,5-사중 치환된 3(2H)-퓨라논[2,2,4,5-tetrasubstituted 3(2H)-furanone] 유도체를 수득하고,The following general formula (II) compound is reacted with 2-haloisobutyryl cyanide or 2-haloisobutyryl halide to give 2,2,4,5-quadically substituted 3 ( 2H )-of general formula (I) Furanone [2,2,4,5-tetrasubstituted 3 ( 2H ) -furanone] derivative is obtained,

필요에 따라 산화제의 존재하에 산화반응을 수행함을 특징으로 한다.If necessary, the oxidation reaction is carried out in the presence of an oxidizing agent.

[화학식 1][Formula 1]

상기 식에서,Where

X는 치환되거나 치환되지 않은 아릴 또는 헤테로 아릴기이고,X is a substituted or unsubstituted aryl or hetero aryl group,

Y는 알킬, 싸이클로알킬, 치환되거나 치환되지 않은 아릴 또는 헤테로 아릴기이다.Y is an alkyl, cycloalkyl, substituted or unsubstituted aryl or hetero aryl group.

상기 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체(Ⅰ)는 하기 반응식 1 내지 3으로 나타낸 방법으로 제조될 수 있다. 따라서, 본 발명에 따른 제조방법을 반응식을 참고로 구체적으로 설명한다.The 2,2,4,5-quaternary substituted 3 ( 2H ) -furanone derivative (I) may be prepared by the method shown in Schemes 1 to 3 below. Therefore, the manufacturing method according to the present invention will be described in detail with reference to the reaction scheme.

본 발명의 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체(Ⅰ)의 제조방법에서 출반물질로 사용되는 에탄온 유도체 화합물(Ⅱ)는, 하기 반응식 1에서와 같이, 화합물 X(Ⅲ)와, 아세틸클로라이드(acetyl chloride) 유도체 (Ⅳ)를 문헌에 공지된 방법(Kor. J. Med. Chem. 1997,7, 34)에 따라 알루미늄클로라이드(AlCl3)촉매하에 메틸렌클로라이드 또는 클로로포름 용매에서 반응시켜 약 50 내지 90%의 수율로 제조할 수 있다.The ethanone derivative compound (II), which is used as a starting material in the preparation method of the 2,2,4,5-quarried substituted 3 ( 2H ) -furanone derivative (I) of the present invention, is as in Scheme 1 below. Compounds X (III) and acetyl chloride derivatives (IV) were subjected to methylene chloride under an aluminum chloride (AlCl 3 ) catalyst according to methods known in the literature ( Kor. J. Med. Chem. 1997 , 7 , 34). Or by reacting in a chloroform solvent in a yield of about 50 to 90%.

(식중, X는 치환되거나 치환되지 않은 아릴 또는 헤테로 아릴기를 갖는 화합물이고, Y는 알킬, 싸이클로알킬, 치환되거나 치환되지 않은 아릴 또는 헤테로 아릴기이다.)Wherein X is a compound having a substituted or unsubstituted aryl or heteroaryl group, and Y is an alkyl, cycloalkyl, substituted or unsubstituted aryl or heteroaryl group.)

다음, 하기 반응식 2에서와 같이, 에탄온 유도체 화합물(Ⅱ)을 2-할로이소부티릴시아나이드(2-haloisobutyryl cyanide) 또는 2-할로이소부티릴할라이드와 반응시키면 C-아실레이션된 중간체 화합물 (Ⅵ)이 생성되며, 이를 분리, 정제없이 계속해서 상온에서 교반하면 2,2,4,5-사중 치환된 3(2H)-퓨라논 화합물(Ia)이 생성된다. 이 반응은 비반응성 용매와 염기 존재하에서 수행할 수 있으며, 1시간에서 7시간이면 완결된다.Next, as shown in Scheme 2, the ethanone derivative compound (II) is reacted with 2-haloisobutyryl cyanide or 2-haloisobutyryl halide to obtain a C-acylated intermediate compound ( VI) is produced, which is continuously stirred at room temperature without separation and purification to yield 2,2,4,5-quarried 3 ( 2H ) -furanone compound (Ia). This reaction can be carried out in the presence of an unreactive solvent and a base, which is completed in 1 to 7 hours.

(식중, B는 할로겐 원자이다.)(Wherein B is a halogen atom)

일반적으로 엔올레이트(enolate)와 아실할라이드(acyl halide)와의 반응은 반응 조건에 따라 C-아실레이션과 O-아실레이션이 되는 비율이 달라지는데, 상기 반응식 2에서 화합물 (Ⅱ)의 엔올레이트의 경우에는 2-할로이소부티릴할라이드(2-haloisobutyryl halide)와 반응하면 O-아실레이션된 화합물을 주로 생성하게 된다(비교예 1). 따라서, 본 발명의 바람직한 실시예에서는 2-할로이소부티릴할라이드의 카르보닐기보다 연성(softness)을 증가시킨 2-할로이소부티릴시아나이드를 화합물 (Ⅱ)의 엔올레이트와 반응시켜 C-아실레이션 반응이 선택적으로 일어나도록 한다.In general, the reaction between enolate and acyl halide varies depending on the reaction conditions of C-acylation and O-acylation. In the case of the enolate of compound (II) in Scheme 2, Reaction with 2-haloisobutyryl halide produces mainly O-acylated compounds (Comparative Example 1). Therefore, in a preferred embodiment of the present invention, the C-acylation reaction is carried out by reacting 2-haloisobutyryl cyanide, which has increased softness than the carbonyl group of 2-haloisobutyryl halide, with the enolate of compound (II). This happens selectively.

한편, 상기 반응에서 염기로써 브로모마그네슘디이소프로필아마이드와 같이 산소와 강하게 결합하는 마그네슘 이온을 가진 염기를 사용하는 경우에는, 2-할로이소부티릴시아나이드 대신에 2-할로이소부티릴할라이드를 사용하여도 C-아실레이션된 화합물 (Ⅵ)이 생성된다.On the other hand, when using a base having a magnesium ion strongly bound to oxygen, such as bromo magnesium diisopropylamide in the reaction, 2-haloisobutyryl halide instead of 2-haloisobutyryl cyanide Use also yields C-acylated compounds (VI).

본 발명에서 사용된 에탄온 유도체 화합물 (Ⅱ)는 그 종류가 특별히 한정되지는 않지만, 일반식 (Ⅱ) 중,Although the kind is not specifically limited in the ethanone derivative compound (II) used by this invention, In general formula (II),

X는 페닐, 티에닐, 나프틸, 피리딜, N-메틸피라졸릴, N-메틸이미다졸릴, 피라진일, N-메틸피롤일, N-메틸인돌일, 벤조퓨란일, 벤조티에닐(benzthienyl), 퀴놀일, 티아졸일(thiazolyl), 옥사졸일기, 또는X is phenyl, thienyl, naphthyl, pyridyl, N-methylpyrazolyl, N-methylimidazolyl, pyrazinyl, N-methylpyrroylyl, N-methylindolyl, benzofuranyl, benzothienyl (benzthienyl ), Quinolyl, thiazolyl, oxazolyl, or

알킬, 할로알킬, 알콕시, 알콕시알킬, 알킬티오, 알킬술포닐, 알킬술피닐, 디알킬아미노, 나이트릴, 니트로, 알킬렌디옥시, 페닐 또는 모르폴리노기 등이 치환된 아릴기 등이고,An aryl group substituted with alkyl, haloalkyl, alkoxy, alkoxyalkyl, alkylthio, alkylsulfonyl, alkylsulfinyl, dialkylamino, nitrile, nitro, alkylenedioxy, phenyl or morpholino group,

Y는 알킬, 싸이클로알킬, 페닐, 티에닐, 나프틸, 피리딜, N-메틸피라졸릴, N-메틸이미다졸릴, 피라진일, N-메틸피롤일, N-메틸인돌일, 벤조퓨란일, 벤조티에닐(benzthienyl), 퀴놀일, 티아졸일(thiazolyl), 옥사졸일기, 또는Y is alkyl, cycloalkyl, phenyl, thienyl, naphthyl, pyridyl, N-methylpyrazolyl, N-methylimidazolyl, pyrazinyl, N-methylpyrroyl, N-methylindolyl, benzofuranyl, Benzothienyl, quinolyl, thiazolyl, oxazolyl groups, or

알킬, 할로알킬, 알콕시, 알콕시알킬, 알킬티오, 알킬술포닐, 알킬술피닐, 디알킬아미노, 나이트릴, 니트로, 알킬렌디옥시, 페닐 또는 모르폴리노기 등이 치환된 아릴기 등이다.And aryl groups substituted with alkyl, haloalkyl, alkoxy, alkoxyalkyl, alkylthio, alkylsulfonyl, alkylsulfinyl, dialkylamino, nitrile, nitro, alkylenedioxy, phenyl or morpholino group and the like.

바람직하게는,Preferably,

X는 페닐기, 또는X is a phenyl group, or

할로겐, 탄소수 1 내지 5의 알킬, 탄소수 1 내지 5의 할로알킬, 탄소수 1 내지 5의 알콕시, 니트로, 탄소수 1 내지 3의 알킬티오, 탄소수 1 내지 3의 알킬술포닐 또는 탄소수 1 내지 3의 알킬술피닐이 치환된 페닐기이고,Halogen, alkyl of 1 to 5 carbon atoms, haloalkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, nitro, alkylthio of 1 to 3 carbon atoms, alkylsulfonyl of 1 to 3 carbon atoms, or alkyl of 1 to 3 carbon atoms Finyl is a substituted phenyl group,

Y는 탄소수 1 내지 6의 알킬, 페닐, 티에닐, 또는Y is alkyl having 1 to 6 carbon atoms, phenyl, thienyl, or

할로겐, 탄소수 1 내지 5의 알킬, 탄소수 1 내지 5의 할로알킬, 탄소수 1 내지 5의 알콕시, 니트로, 탄소수 1 내지 3의 알킬티오, 탄소수 1 내지 3의 알킬술포닐 또는 탄소수 1 내지 5의 알킬술피닐이 치환된 페닐기이다.Halogen, alkyl of 1 to 5 carbon atoms, haloalkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, nitro, alkylthio of 1 to 3 carbon atoms, alkylsulfonyl of 1 to 3 carbon atoms or alkylsulfonate of 1 to 5 carbon atoms Finyl is a substituted phenyl group.

본 발명의 방법에서 사용된 2-할로이소부티릴시아나이드 및 2-할로이소부티릴할라이드(V)는 그 종류가 특별히 한정되지는 않지만, 2-브로모이소부티릴시아나이드, 2-클로로이소부티릴시아나이드, 2-브로모이소부티릴브로마이드, 2-클로로이소부티릴브로마이드, 2-클로로이소부티릴브로마이드 또는 2-클로로이소부티릴클로라이드가 바람직하다.The 2-haloisobutyryl cyanide and 2-haloisobutyryl halide (V) used in the method of the present invention are not particularly limited in kind, but 2-bromoisobutyryl cyanide, 2-chloroiso Preference is given to butyryl cyanide, 2-bromoisobutyryl bromide, 2-chloroisobutyryl bromide, 2-chloroisobutyryl bromide or 2-chloroisobutyryl chloride.

상기 반응에서 사용된 염기는, 그 종류가 특별히 한정되지는 않지만, 예를 들면, 소디움 하이드라이드, 리튬t-부톡사이드, 포타시움t-부톡사이드, 소디움t-부톡사이드, 리튬디이소프로필아마이드, 소디움비스(트리메틸실릴)아마이드, 포타시움비스(트리메틸실릴)아마이드, 리튬비스(트리메틸실릴)아마이드, 브로모마그네슘디이소프로필아마이드 등이 바람직하며, 소디움 하이드라이드, 포타시움t-부톡사이드, 소디움비스(트리메틸실릴)아마이드, 브로모마그네슘디이소프로필아마이드 등이 더욱 바람직하다.Although the kind used in the said reaction is not specifically limited, For example, sodium hydride, lithium t -butoxide, a potassium t -butoxide, sodium t -butoxide, lithium diisopropylamide, sodium Bis (trimethylsilyl) amide, Potassium bis (trimethylsilyl) amide, Lithium bis (trimethylsilyl) amide, Bromomagnesium diisopropylamide, and the like are preferable, and sodium hydride, potassium t -butoxide, sodium bis (trimethylsilyl ), Bromo magnesium diisopropylamide, and the like are more preferable.

이들은 에탄온 유도체 화합물(Ⅱ)에 대해 1 당량 이상으로 사용할 수 있으며, 바람직하게는 2~3 당량으로 사용할 수 있다. 염기를 약 2당량 미만으로 사용하면, 화합물 (Ia)보다는 화합물 (Ⅵ)이 많이 생겨, 다시 고리화 반응을 추가로 하여야 하는 문제점이 있고, 약 3당량으로 사용하면 화합물 (Ia)가 대부분 얻어지기때문에 3당량 이상으로 사용하는 것은 큰 잇점이 없으므로, 2~3당량으로 사용하는 것이 바람직하다.These can be used in 1 equivalent or more with respect to the ethanone derivative compound (II), Preferably it can be used in 2-3 equivalents. If the base is used in less than about 2 equivalents, the compound (VI) is more produced than the compound (Ia), and there is a problem in that a cyclization reaction is added again. When the compound is used in about 3 equivalents, most of the compound (Ia) is obtained. Therefore, the use of more than 3 equivalents is not a big advantage, it is preferable to use in 2 to 3 equivalents.

본 발명의 방법에서 사용된 유기 용매로는 상술한 염기와 반응성이 없는 용매를 사용하는 것이 바람직한데, 예를 들면, 에테르 화합물, 방향족 화합물, 디메틸포름아마이드, 디메틸설폭사이드 등을 사용할 수 있다. 에테르 화합물로는 디메틸에테르, 디이소프로필에테르, 디부틸에테르, 테트라하이드로퓨란, 디옥산, 1,2-디메톡시에탄 등이 가능하며, 방향족 화합물로는 벤젠, 톨루엔, 자일렌 등이 가능하다. 바람직하기로는 테트라하이드로퓨란, 디옥산, 톨루엔, 디메틸포름아마이드이다.As the organic solvent used in the method of the present invention, it is preferable to use a solvent which is not reactive with the above-described base. For example, an ether compound, an aromatic compound, dimethylformamide, dimethyl sulfoxide and the like can be used. Examples of the ether compound include dimethyl ether, diisopropyl ether, dibutyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and the like, and aromatic compounds include benzene, toluene, xylene and the like. Preferred are tetrahydrofuran, dioxane, toluene and dimethylformamide.

본 발명의 방법에서, 에탄온 유도체 화합물 (Ⅱ)와 2-할로이소부티릴시아나이드(Ⅴ)의 반응은 -70~25℃의 온도, 바람직하게는 -20~5℃의 온도에서 수행하는 것이 바람직하다.In the process of the present invention, the reaction of the ethanone derivative compound (II) with 2-haloisobutyryl cyanide (V) is carried out at a temperature of -70 to 25 ° C, preferably at a temperature of -20 to 5 ° C. desirable.

본 발명의 방법에서, 상기 반응식 2에 의해 제조된 화합물이 X가 알킬티오페닐기인 화합물인 경우, 이 화합물 (Ib)를 산화제로 산화시켜, X가 알킬술포닐페닐기 또는 알킬술피닐페닐기인 화합물 (Ic)를 제조할 수 있다(반응식 3). 산화제로는 m-클로로퍼옥시벤조산 (m-chloroperoxybenzoic acid), 옥손(potassium peroxymonosulfate; OXONE), 퍼옥시벤조산, 소디움퍼카보네이트(Na2CO3-1.5H2O2), 과산화수소를 사용할 수 있다.In the method of the present invention, when the compound prepared by the above Scheme 2 is a compound in which X is an alkylthiophenyl group, the compound (Ib) is oxidized with an oxidizing agent so that X is an alkylsulfonylphenyl group or an alkylsulfinylphenyl group ( Ic) can be prepared (Scheme 3). As the oxidizing agent, m-chloroperoxybenzoic acid (m-chloroperoxybenzoic acid), oxone (potassium peroxymonosulfate (OXONE)), peroxybenzoic acid, sodium percarbonate (Na 2 CO 3 -1.5H 2 O 2 ), and hydrogen peroxide can be used.

(식중 R은 알킬기이고, n은 1또는 2이다.)Wherein R is an alkyl group and n is 1 or 2.

이하 본 발명을 실시예를 통하여 구체적으로 설명하지만, 본 발명이 이들 예로만 한정되는 것은 아니다. 한편, 하기에서 예비제조예 1-16은 실시예에서 사용되는 에탄온 유도체 화합물(Ⅱ)의 제조방법이다.Hereinafter, the present invention will be described in detail with reference to Examples, but the present invention is not limited only to these examples. On the other hand, in Preparation Example 1-16 below is a method for producing the ethanone derivative compound (II) used in the Examples.

예비제조예 1. 2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온Preparatory Example 1. 2- (3-Fluorophenyl) -1- (4-methylthiophenyl) ethanone

알루미늄클로라이드 77.3g을 메틸렌클로라이드 600㎖에 현탁시켰다. 빙수욕에서 3-플루오르페닐아세틸클로라이드 100g을 적가하고, 10분 후 티오아니솔 68㎖를 10분 동안 적가하였다. 빙수욕에서 1시간, 상온에서 1시간 동안 교반한 다음, 반응액을 8% 염산수 1ℓ에 붓고 1시간 동안 교반하였다. 유기층을 분리하고, 소금수로 세척한 다음, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 셀라이트를 이용하여 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 메틸렌클로라이드-헥산에서 결정화하여 표제 화합물 142.9g(94.8%)을 얻었다.77.3 g of aluminum chloride was suspended in 600 ml of methylene chloride. 100 g of 3-fluorophenylacetylchloride was added dropwise in an ice water bath, and after 10 minutes, 68 ml of thioanisole was added dropwise for 10 minutes. After stirring for 1 hour in an ice water bath and 1 hour at room temperature, the reaction solution was poured into 1 L of 8% hydrochloric acid and stirred for 1 hour. The organic layer was separated, washed with brine, and dried over anhydrous magnesium sulfate. The insolubles were filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in methylene chloride-hexane to give 142.9 g (94.8%) of the title compound.

m.p.: 94.5~95.5℃m.p .: 94.5 ~ 95.5 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.52(s, 3H), 4.23(s, 2H), 6.95-7.05(m, 3H), 7.25-7.30(m, 3H), 7.91(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.52 (s, 3H), 4.23 (s, 2H), 6.95-7.05 (m, 3H), 7.25-7.30 (m, 3H), 7.91 (d, J = 8.4 Hz, 2H)

예비제조예 2. 1-(4-메틸티오페닐)-2-페닐에탄온Preparatory Example 2. 1- (4-Methylthiophenyl) -2-phenylethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 페닐아세틸클로라이드 18g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 25.8g(89.9%)을 얻었다.Except for using 18 g of phenylacetyl chloride instead of 100 g of 3-fluorophenylacetyl chloride, the same procedure as in Preparation Example 1 was carried out to obtain 25.8 g (89.9%) of the title compound.

m.p.: 99~100℃m.p .: 99 ~ 100 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.51(s, 3H), 4.24(s, 2H), 7.21-7.39(m, 7H), 7.92(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.51 (s, 3H), 4.24 (s, 2H), 7.21-7.39 (m, 7H), 7.92 (d, J = 8.7Hz, 2H)

예비제조예 3. 2-(3-클로로페닐)-1-(4-메틸티오페닐)에탄온Preparatory Example 3. 2- (3-Chlorophenyl) -1- (4-methylthiophenyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 3-클로로페닐아세틸클로라이드 10.55g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 11.7g(79.4%)을 얻었다.11.7 g (79.4%) of the title compound was obtained in the same manner as the Preparative Example 1, except that 10.55 g of 3-chlorophenylacetyl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p.: 81~82℃m.p .: 81 ~ 82 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.52(s, 3H), 4.21(s, 2H), 7.12-7.15(m, 1H), 7.23-7.28(m, 5H), 7.90(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.52 (s, 3H), 4.21 (s, 2H), 7.12-7.15 (m, 1H), 7.23-7.28 (m, 5H), 7.90 (d, J = 8.4 Hz, 2H)

예비제조예 4. 1-(4-메틸티오페닐)-2-(3-트리플루오르메틸페닐)에탄온Preparatory Example 4. 1- (4-Methylthiophenyl) -2- (3-trifluoromethylphenyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 3-트리플루오르페닐아세틸클로라이드 2.5g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 2.61g(74.9%)을 얻었다.2.61 g (74.9%) of the title compound were obtained in the same manner as the pre-preparation example 1 except that 2.5 g of 3-trifluorophenylacetyl chloride was used instead of 100 g of 3-fluorophenylacetyl chloride.

m.p.: 63~64℃m.p .: 63 ~ 64 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.53(s, 3H), 4.31(s, 2H), 7.28(d,J=8.4Hz, 2H), 7.44-7.46(m, 2H), 7.52(br, 2H), 7.92(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.53 (s, 3H), 4.31 (s, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.44-7.46 (m, 2H), 7.52 (br) , 2H), 7.92 (d, J = 8.4 Hz, 2H)

예비제조예 5. 2-(4-니트로페닐)-1-(4-메틸티오페닐)에탄온Preparatory Example 5. 2- (4-Nitrophenyl) -1- (4-methylthiophenyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 4-니트로페닐아세틸클로라이드 3.2g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 2.73g(59.3%)을 얻었다.Except for using 3.2 g of 4-nitrophenylacetyl chloride instead of 100 g of 3-fluorophenylacetyl chloride, the same procedure as in Preparation Example 1 was carried out to obtain 2.73 g (59.3%) of the title compound.

m.p.: 186~187℃m.p .: 186 ~ 187 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.53(s, 3H), 4.37(s, 2H), 7.29(d,J=8.7Hz, 2H), 7.43(d,J=9.0Hz, 2H), 7.91(d,J=8.4Hz, 2H), 8.20(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.53 (s, 3H), 4.37 (s, 2H), 7.29 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 9.0 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H), 8.20 (d, J = 8.7 Hz, 2H)

예비제조예 6. 2-(4-메톡시페닐)-1-(4-메틸티오페닐)에탄온Preparatory Example 6. 2- (4-methoxyphenyl) -1- (4-methylthiophenyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 4-메톡시페닐아세틸클로라이드 5.38g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 4.5g(56.7%)을 얻었다.4.5 g (56.7%) of the title compound was obtained in the same manner as in Preparative Example 1, except that 5.38 g of 4-methoxyphenylacetyl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p.: 123~124℃m.p .: 123 ~ 124 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.50(s, 3H), 3.77(s, 3H), 4.17(s, 2H), 6.85(d,J=8.7Hz, 2H), 7.17(d,J=8.7Hz, 2H), 7.24(d,J=8.7Hz, 2H), 7.90(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.50 (s, 3H), 3.77 (s, 3H), 4.17 (s, 2H), 6.85 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 7.90 (d, J = 8.7 Hz, 2H)

예비제조예 7. 2-(2,5-디플루오르페닐)-1-(4-메틸티오페닐)에탄온Preparatory Example 7. 2- (2,5-Difluorophenyl) -1- (4-methylthiophenyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 2,5-디플루오르페닐아세틸클로라이드 7.75g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 5.71g(50.4%)을 얻었다.5.71 g (50.4%) of the title compound was obtained by the same method as the preparative example 1, except that 7.75 g of 2,5-difluorophenylacetyl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p.: 103~104℃m.p .: 103 ~ 104 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.53(s, 3H), 4.25(s, 2H), 6.94-7.07(m, 3H), 7.29(d,J=8.7Hz, 2H), 7.93(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.53 (s, 3H), 4.25 (s, 2H), 6.94-7.07 (m, 3H), 7.29 (d, J = 8.7 Hz, 2H), 7.93 (d , J = 8.7 Hz, 2H)

예비제조예 8. 2-(3,5-디플루오르페닐)-1-(4-메틸티오페닐)에탄온Preparatory Example 8. 2- (3,5-Difluorophenyl) -1- (4-methylthiophenyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 3,5-디플루오르페닐아세틸클로라이드 30g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 32.42g(73.9%)을 얻었다.32.42 g (73.9%) of the title compound was obtained in the same manner as the preparative example 1 except that 30 g of 3,5-difluorophenylacetyl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p.: 113~114℃m.p .: 113 ~ 114 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.53(s, 3H), 4.22(s, 2H), 6.71-6.81(m, 3H), 7.27(d,J=8.7Hz, 2H), 7.90(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.53 (s, 3H), 4.22 (s, 2H), 6.71-6.81 (m, 3H), 7.27 (d, J = 8.7 Hz, 2H), 7.90 (d , J = 8.7 Hz, 2H)

예비제조예 9. 1-(4-메틸티오페닐)-2-(2-티에닐)에탄온Preparatory Example 9. 1- (4-Methylthiophenyl) -2- (2-thienyl) ethanone

3-플루오르페닐아세틸클로라이드 100g 대신에 2-티오펜아세틸클로라이드 2㎖를 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 145mg(3.6%)을 얻었다.145 mg (3.6%) of the title compound were obtained in the same manner as in Preparative Example 1, except that 2 ml of 2-thiophene acetyl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p.: 72~73℃m.p .: 72 ~ 73 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.52(s, 3H), 4.44(s, 2H), 6.93-6.98(m, 2H), 7.22(dd,J=5.7, 1.5Hz,1H),7.25(d,J=7.8Hz, 2H), 7.93(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.52 (s, 3H), 4.44 (s, 2H), 6.93-6.98 (m, 2H), 7.22 (dd, J = 5.7, 1.5 Hz, 1H) , 7.25 (d, J = 7.8Hz, 2H), 7.93 (d, J = 8.4Hz, 2H)

예비제조예 10. 1-(4-메틸티오페닐)프로판온Preparatory Example 10. 1- (4-Methylthiophenyl) propanone

3-플루오르페닐아세틸클로라이드 100g 대신에 프로피오닐클로라이드 2.5㎖를 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 3.7g(71.3%)을 얻었다.3.7 g (71.3%) of the title compound was obtained in the same manner as the preparative example 1, except that 2.5 ml of propionyl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p: 63~64℃m.p: 63 ~ 64 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.22(t,J=6.9Hz, 3H), 2.52(s, 3H), 2.96(q,J=6.9Hz, 2H), 7.26(d,J=8.4Hz, 2H), 7.88(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.22 (t, J = 6.9 Hz, 3H), 2.52 (s, 3H), 2.96 (q, J = 6.9 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.7 Hz, 2H)

예비제조예 11. 4-메틸-1-(4-메틸티오페닐)펜탄온Preparatory Example 11 4-Methyl-1- (4-methylthiophenyl) pentanone

3-플루오르페닐아세틸클로라이드 100g 대신에 이소발레릴클로라이드 3g을 사용한다는 것을 제외하고는 예비제조예 1과 동일한 방법으로 실시하여 표제 화합물 4.33g(83.6%)을 얻었다.4.33 g (83.6%) of the title compound was obtained by the same method as the preparative example 1, except that 3 g of isovaleryl chloride was used instead of 100 g of 3-fluorophenylacetylchloride.

m.p.: 51~52℃m.p .: 51 ~ 52 ℃

1H-NMR(CDCl3, 300MHz, δ) 0.99(d,J=6.6Hz, 6H), 2.80(sept,J=6.6Hz, 1H), 2.52(s, 3H), 2.79(d,J=7.2Hz, 2H), 7.26(d,J=8.4Hz, 2H), 7.87(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 0.99 (d, J = 6.6 Hz, 6H), 2.80 (sept, J = 6.6 Hz, 1H), 2.52 (s, 3H), 2.79 (d, J = 7.2 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 8.7 Hz, 2H)

예비제조예 12. 2-(2-클로로페닐)-1-(3-플루오르-4-메틸티오페닐)에탄온Preparatory Example 12. 2- (2-Chlorophenyl) -1- (3-fluoro-4-methylthiophenyl) ethanone

2-플루오르티오아니솔 3g을 메틸렌클로라이드 30㎖에 녹인다음, 빙수욕에서 알루미늄클로라이드 2.81g을 적가하였다. 10분 후, 메틸렌클로라이드 20㎖에 녹인 2-클로로페닐아세틸클로라이드 4.39g을 10분 동안 적가하였다. 빙수욕에서 1시간, 상온에서 하룻밤동안 교반한 다음, 반응액을 8% 염산수 50㎖에 붓고 1시간 동안 교반하였다. 유기층을 분리하고, 소금수로 세척하였다. 무수 황산마그네슘을 가하여 건조하였다. 불용물을 셀라이트를 이용하여 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 에틸아세테이트-헥산에서 결정화하여 표제 화합물 1.55g(27.8%)을 얻었다.3 g of 2-fluorothioanisole was dissolved in 30 ml of methylene chloride, and then 2.81 g of aluminum chloride was added dropwise in an ice water bath. After 10 minutes, 4.39 g of 2-chlorophenylacetylchloride dissolved in 20 ml of methylene chloride was added dropwise for 10 minutes. After stirring for 1 hour in an ice-water bath at room temperature overnight, the reaction solution was poured into 50 ml of 8% hydrochloric acid and stirred for 1 hour. The organic layer was separated and washed with brine. Anhydrous magnesium sulfate was added and dried. The insolubles were filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in ethyl acetate-hexane to give 1.55 g (27.8%) of the title compound.

m.p.: 72~73℃m.p .: 72 ~ 73 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.53(s, 3H), 4.37(s, 2H), 7.26(m, 4H), 7.41(m, 1H), 7.67(m, 1H), 7.81(m, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.53 (s, 3H), 4.37 (s, 2H), 7.26 (m, 4H), 7.41 (m, 1H), 7.67 (m, 1H), 7.81 (m , 1H)

예비제조예 13. 1-(2-플루오르-4-메틸티오페닐)-2-(3-플루오르페닐)에탄온Preparatory Example 13. 1- (2-Fluoro-4-methylthiophenyl) -2- (3-fluorophenyl) ethanone

2-플루오르티오아니솔 3g과 2-클로로페닐아세틸클로라이드 4.39g 대신에 3-플루오르티오아니솔 4.12g과 3-플루오르페닐아세틸클로라이드 5g를 사용한다는 것을 제외하고는 예비제조예 12와 동일한 방법으로 실시하여 표제 화합물 5.4g(67%)을 얻었다.The procedure was carried out in the same manner as in Preparation Example 12, except that 4.12 g of 3-fluorothioanisole and 5 g of 3-fluorophenylacetylchloride were used instead of 3 g of 2-fluorothioanisole and 4.39 g of 2-chlorophenylacetylchloride. This gave 5.4 g (67%) of the title compound.

m.p.: 67~68℃m.p .: 67 ~ 68 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.51(s, 3H), 4.24(s, 2H), 6.91-7.56(m, 5H),7.26(m, 1H), 7.81(m, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.51 (s, 3H), 4.24 (s, 2H), 6.91-7.56 (m, 5H), 7.26 (m, 1H), 7.81 (m, 1H)

예비제조예 14. 1-(3-브로모-4-메틸티오페닐)-2-(2,5-디플루오르페닐)에탄온Preparatory Example 14. 1- (3-Bromo-4-methylthiophenyl) -2- (2,5-difluorophenyl) ethanone

2-플루오르티오아니솔 3g과 2-클로로페닐아세틸클로라이드 4.39g 대신에 2-브로모티오아니솔 1.7g과 2,5-디플루오르페닐아세틸클로라이드 1.79g을 사용한다는 것을 제외하고는 예비제조예 12와 동일한 방법으로 실시하여 표제 화합물 2.32g(77.6%)을 제조하였다.Preparative Example 12 except that 1.7 g of 2-bromothioanisole and 1.79 g of 2,5-difluorophenylacetylchloride were used instead of 3 g of 2-fluorothioanisole and 4.39 g of 2-chlorophenylacetylchloride. 2.32 g (77.6%) of the title compound were prepared in the same manner as the method.

m.p.: 143~144℃m.p .: 143 ~ 144 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.53(s, 3H), 4.24(s, 2H), 6.95(m, 2H), 7.05(m, 1H), 7.18(d,J=8.1Hz, 1H), 7.94(dd,J=8.1, 1.8Hz, 1H), 8.16(d,J=2.1Hz, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.53 (s, 3H), 4.24 (s, 2H), 6.95 (m, 2H), 7.05 (m, 1H), 7.18 (d, J = 8.1Hz, 1H ), 7.94 (dd, J = 8.1, 1.8 Hz, 1H), 8.16 (d, J = 2.1 Hz, 1H)

예비제조예 15. 1-(3-클로로-4-메틸티오페닐)-2-(3-플루오르페닐)에탄온Preparatory Example 15. 1- (3-Chloro-4-methylthiophenyl) -2- (3-fluorophenyl) ethanone

2-플루오르티오아니솔 3g과 2-클로로페닐아세틸클로라이드 4.39g 대신에 2-클로로티오아니솔 4g과 3-플루오르페닐아세틸클로라이드 5g을 사용하다는 것을 제외하고는 예비제조예 12와 동일한 방법으로 실시하여 표제 화합물 3.3g(44.4%)을 얻었다.In the same manner as in Preparation Example 12, except that 4 g of 2-chlorothioanisole and 5 g of 3-fluorophenylacetyl chloride were used instead of 3 g of 2-fluorothioanisole and 4.39 g of 2-chlorophenylacetyl chloride. 3.3 g (44.4%) of the title compound were obtained.

m.p.: 95~96℃m.p .: 95 ~ 96 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.52(s, 3H), 4.23(s, 2H), 6.99(m, 3H), 7.19(d,J=8.1Hz, 1H), 7.34(m, 1H), 7.86(dd,J=8.4, 1.8Hz, 1H), 7.96(d,J=1.8Hz, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.52 (s, 3H), 4.23 (s, 2H), 6.99 (m, 3H), 7.19 (d, J = 8.1 Hz, 1H), 7.34 (m, 1H ), 7.86 (dd, J = 8.4, 1.8 Hz, 1H), 7.96 (d, J = 1.8 Hz, 1H)

예비제조예 16. 2-(3,5-디플루오르페닐)-1-(3-메틸-4-메틸티오페닐)에탄온Preparatory Example 16. 2- (3,5-Difluorophenyl) -1- (3-methyl-4-methylthiophenyl) ethanone

2-플루오르티오아니솔 3g과 2-클로로페닐아세틸클로라이드 4.39g 대신에 2-메틸티오아니솔 1.21g과 3,5-디플루오르페닐아세틸클로라이드 1.4㎖를 사용한다는 것을 제외하고는 예비제조예 12와 동일한 방법으로 실시하여 표제 화합물 0.87g(34%)을 얻었다.Pre-Production Example 12 except that 1.21 g of 2-methylthioanisole and 1.4 ml of 3,5-difluorophenylacetyl chloride were used instead of 3 g of 2-fluorothioanisole and 4.39 g of 2-chlorophenylacetylchloride. In the same manner, 0.87 g (34%) of the title compound were obtained.

m.p.: 73~74℃m.p .: 73 ~ 74 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.35(s, 3H), 2.52(s, 3H), 4.22(s, 2H), 6.70(m, 1H), 6.80(m, 2H), 7.17(d,J=8.1Hz, 1H), 7.74(s, 1H), 7.80(dd,J=8.3, 2.1Hz, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.35 (s, 3H), 2.52 (s, 3H), 4.22 (s, 2H), 6.70 (m, 1H), 6.80 (m, 2H), 7.17 (d , J = 8.1 Hz, 1H), 7.74 (s, 1H), 7.80 (dd, J = 8.3, 2.1 Hz, 1H)

실시예 1. 2,2-디메틸-4-(3-플루오르페닐)-5-(4-메틸티오페닐)-3(Example 1. 2,2-dimethyl-4- (3-fluorophenyl) -5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

[방법 A][Method A]

예비제조예 1의 2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g을 테트라하이드로퓨란 1ℓ에 녹인다음, 빙수욕에서 소디움하이드라이드(95%) 26g을 적가하였다. 이를 상온에서 1시간 동안 교반하고, 다시 빙수욕에서 냉각한 다음, 2-브로모이소부티릴시아나이드 69g을 적가하였다. 5시간 동안 상온에서 교반하고, 반응액에 소량의 정제수를 가한 뒤 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 1ℓ에 녹이고 정제수와 소금수로 세척한 다음, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 메탄올에서 결정화하여 표제 화합물 102g(81%)을 얻었다.100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone of Preparative Preparation Example 1 was dissolved in 1 L of tetrahydrofuran, followed by dropwise addition of 26 g of sodium hydride (95%) in an ice water bath. It was stirred at room temperature for 1 hour, cooled again in an ice-water bath, and 69 g of 2-bromoisobutyryl cyanide was added dropwise. After stirring for 5 hours at room temperature, a small amount of purified water was added to the reaction solution and concentrated under reduced pressure. The obtained residue was dissolved in 1 L of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in methanol to give 102 g (81%) of the title compound.

m.p: 106℃m.p: 106 ° C

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.50(s, 3H), 6.97-7.11(m, 3H), 7.18(d,J=9.0Hz, 2H), 7.26-7.36(m, 1H), 7.55(d,J=9.0Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.50 (s, 3H), 6.97-7.11 (m, 3H), 7.18 (d, J = 9.0 Hz, 2H), 7.26-7.36 (m, 1H), 7.55 (d, J = 9.0 Hz, 2H)

[방법 B][Method B]

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 1g을 테트라하이드로퓨란 10㎖에 녹인다음, 소디움비스(트리메틸실릴)아마이드 3.9㎖(1M/THF)를 적가하였다. 이를 상온에서 1시간 동안 교반하고, 다시 빙수욕에서 냉각한 다음, 2-브로모이소부티릴시아나이드 0.69g을 적가하였다. 7시간 동안 상온에서 교반하고, 반응액에 소량의 정제수를 가한 뒤 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 100㎖에 녹여 정제수와 소금수로 세척하고, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 메탄올에서 결정화하여 표제 화합물 0.78g(61.8%)을 얻었다.1 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone was dissolved in 10 ml of tetrahydrofuran, and then 3.9 ml (1 M / THF) of sodium bis (trimethylsilyl) amide was added dropwise. It was stirred at room temperature for 1 hour, cooled again in an ice water bath, and then 0.69 g of 2-bromoisobutyryl cyanide was added dropwise. After stirring for 7 hours at room temperature, a small amount of purified water was added to the reaction solution and concentrated under reduced pressure. The obtained residue was dissolved in 100 ml of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in methanol to give 0.78 g (61.8%) of the title compound.

[방법 C][Method C]

디에틸에테르 50㎖에 녹인 디이소프로필아민 0.92㎖에 에틸마그네슘브로마이드 5.76㎖(1M/Et2O)을 -70℃에서 적가하고 상온에서 1시간 동안 교반하였다. 이를 -70℃로 냉각한 뒤, 테트라하이드로퓨란 10㎖에 녹인 2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 1g을 적가하고, 반응온도를 상온으로 서서히 올리며 1시간 동안교반하였다. 빙수욕에서 2-브로모이소부티릴브로마이드 1.06g을 적가하고, 2시간 동안 상온에서 교반한 다음, 반응액을 정제수로 세척하고, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 다시 테트라하이드로퓨란 50㎖에 녹이고, 소디움하이드라이드(95%) 0.18g을 적가하였다. 이를 상온에서 2시간 동안 교반한 뒤, 반응액에 소량의 정제수를 가하고, 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 100㎖에 녹여 정제수와 소금수로 세척하고, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 메탄올에서 결정화하여 표제 화합물 0.88g(70%)을 얻었다.5.76 mL (1 M / Et 2 O) of ethylmagnesium bromide was added dropwise at 0.92 mL of diisopropylamine dissolved in 50 mL of diethyl ether at room temperature, and stirred for 1 hour. After cooling to −70 ° C., 1 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone dissolved in 10 ml of tetrahydrofuran was added dropwise, and the reaction temperature was gradually raised to room temperature for 1 hour. Stir for a while. 1.06 g of 2-bromoisobutyryl bromide was added dropwise in an ice water bath, stirred at room temperature for 2 hours, and then the reaction solution was washed with purified water, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in 50 ml of tetrahydrofuran again, and 0.18 g of sodium hydride (95%) was added dropwise. After stirring for 2 hours at room temperature, a small amount of purified water was added to the reaction solution, and concentrated under reduced pressure. The obtained residue was dissolved in 100 ml of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in methanol to give 0.88 g (70%) of the title compound.

[방법 D][Method D]

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 1g을 디메틸포름아마이드 10㎖에 녹인 다음, 빙수욕에서 소디움하이드라이드(95%) 0.26g을 적가하였다. 이를 상온에서 1시간 동안 교반한 다음, 다시 빙수욕에서 냉각하였다. 여기에 2-브로모이소부티릴시아나이드 0.69g을 적가한 후, 5시간 동안 상온에서 교반하고, 반응액에 소량의 정제수를 가한 뒤 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 100㎖에 녹여 정제수와 소금수로 세척하고, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축한 다음, 얻어진 잔사를 메탄올에서 결정화하여 표제 화합물 0.45g(35.7%)을 얻었다.1 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone was dissolved in 10 ml of dimethylformamide, and then 0.26 g of sodium hydride (95%) was added dropwise in an ice water bath. It was stirred at room temperature for 1 hour and then cooled again in an ice-water bath. 0.69 g of 2-bromoisobutyryl cyanide was added dropwise thereto, stirred at room temperature for 5 hours, and a small amount of purified water was added to the reaction solution, followed by concentration under reduced pressure. The obtained residue was dissolved in 100 ml of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. The insolubles were filtered off, the filtrate was concentrated under reduced pressure, and the obtained residue was crystallized in methanol to obtain 0.45 g (35.7%) of the title compound.

[방법 E][Method E]

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 1g을 톨루엔 15㎖에 녹인다음, 빙수욕에서 포타시움t-부톡사이드 1.12g을 적가하였다. 이를 상온에서 1시간 동안 교반하고, 다시 빙수욕에서 냉각한 다음, 2-브로모이소부티릴시아나이드 0.69g을 적가하였다. 그 다음, 5시간 동안 상온에서 교반하고, 정제수와 소금수로 세척한 후, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 메탄올에서 결정화하여 표제 화합물 0.26g(20.6%)을 얻었다.1 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone was dissolved in 15 ml of toluene, and then 1.12 g of potassium fortium t -butoxide was added dropwise in an ice water bath. It was stirred at room temperature for 1 hour, cooled again in an ice water bath, and then 0.69 g of 2-bromoisobutyryl cyanide was added dropwise. Then, the mixture was stirred at room temperature for 5 hours, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in methanol to give 0.26 g (20.6%) of the title compound.

실시예 2. 2,2-디메틸-5-(4-메틸티오페닐)-4-페닐-3(Example 2. 2,2-dimethyl-5- (4-methylthiophenyl) -4-phenyl-3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 2의 1-(4-메틸티오페닐)-2-페닐에탄온 2g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 실시하여 표제 화합물 2.51g(80.0%)을 얻었다.Except for using 2 g of 1- (4-methylthiophenyl) -2-phenylethanone of Preparative Example 2 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone. Was carried out in the same manner as in Method A of Example 1 to obtain 2.51 g (80.0%) of the title compound.

m.p.: 109~110℃m.p .: 109 ~ 110 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.49(s, 3H), 7.16(d,J=8.7Hz, 2H), 7.27-7.55(m, 5H), 7.56(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.49 (s, 3H), 7.16 (d, J = 8.7 Hz, 2H), 7.27-7.55 (m, 5H), 7.56 (d , J = 8.7 Hz, 2H)

실시예 3. 4-(3-클로로페닐)-2,2-디메틸-5-(4-메틸티오페닐)-3(Example 3. 4- (3-chlorophenyl) -2,2-dimethyl-5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 3의 2-(3-클로로페닐)-1-(4-메틸티오페닐)에탄온 11.4g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 10.98g(77.3%)을 얻었다.11.4 g of 2- (3-chlorophenyl) -1- (4-methylthiophenyl) ethanone of Preparative Example 3 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone Reaction was carried out in the same manner as in Method A of Example 1, except that the pure portion was separated by column chromatography (ethyl acetate: hexane = 1: 6) to obtain 10.98 g (77.3%) of the title compound. .

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.49(s, 3H), 7.15-7.22(m, 3H), 7.27-7.31(m, 2H), 7.33-7.36(m, 1H), 7.54(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.49 (s, 3H), 7.15-7.22 (m, 3H), 7.27-7.31 (m, 2H), 7.33-7.36 (m, 1H), 7.54 (d, J = 8.7Hz, 2H)

실시예 4. 2,2-디메틸-5-(4-메틸티오페닐)-4-(3-트리플루오르메틸페닐)-3(Example 4. 2,2-dimethyl-5- (4-methylthiophenyl) -4- (3-trifluoromethylphenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 4의1-(4-메틸티오페닐)-2-(3-트리플루오르메틸페닐)에탄온 2.25g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 1.2g(43.7%)을 얻었다.2- (3-methylthiophenyl) -2- (3-trifluoromethylphenyl) ethanone of Preparative Example 4 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone 2.25 The reaction was carried out in the same manner as in Method A of Example 1, except that g was used, and then 1.2 g (43.7%) of the titled compound was separated by column chromatography (ethyl acetate: hexane = 1: 6). Got it.

1H-NMR(CDCl3, 300MHz, δ) 1.56(s, 6H), 2.49(s, 3H), 7.18(d,J=9.0Hz, 2H), 7.51-7.62(m, 6H). 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.56 (s, 6H), 2.49 (s, 3H), 7.18 (d, J = 9.0 Hz, 2H), 7.51-7.62 (m, 6H).

실시예 5. 2,2-디메틸-5-(4-메틸티오페닐)-4-(4-니트로페닐)-3(Example 5. 2,2-dimethyl-5- (4-methylthiophenyl) -4- (4-nitrophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 5의 2-(4-니트로페닐)-1-(4-메틸티오페닐)에탄온 1g을 사용한다는 것을 제외하고 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 0.70g(56.6%)을 얻었다.Instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone, 1 g of 2- (4-nitrophenyl) -1- (4-methylthiophenyl) ethanone of Preparation Example 5 was added. The reaction mixture was carried out in the same manner as in Method A of Example 1, except that the residue was purified by column chromatography (ethyl acetate: hexane = 1: 6) to obtain 0.70 g (56.6%) of the title compound.

1H-NMR(CDCl3, 300MHz, δ) 1.57(s, 6H), 2.51(s, 3H), 7.21(d,J=8.7Hz, 2H), 7.53(d,J=8.7Hz, 2H), 7.54(d,J=9.0Hz, 2H), 8.21(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.57 (s, 6H), 2.51 (s, 3H), 7.21 (d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 9.0 Hz, 2H), 8.21 (d, J = 8.7 Hz, 2H)

실시예 6. 2,2-디메틸-4-(4-메톡시페닐)-5-(4-메틸티오페닐)-3(Example 6. 2,2-dimethyl-4- (4-methoxyphenyl) -5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 6의 2-(4-메톡시페닐)-1-(4-메틸티오페닐)에탄온 3.01g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 실시하여 표제 화합물 1.51g(40.1%)을 얻었다.2- (4-methoxyphenyl) -1- (4-methylthiophenyl) ethanone 3.01 of Preparative Example 6 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone 1.51 g (40.1%) of the title compound was obtained by the same method as the method A of Example 1, except that g was used.

m.p.: 116~117℃m.p .: 116 ~ 117 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.54(s, 6H), 2.49(s, 3H), 3.83(s, 3H), 6.91(d,J=9.0Hz, 2H), 7.16(d,J=8.7Hz, 2H), 7.23(d,J=9.0Hz, 2H), 7.53(d,J=8.7Hz, 2H). 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.54 (s, 6H), 2.49 (s, 3H), 3.83 (s, 3H), 6.91 (d, J = 9.0 Hz, 2H), 7.16 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 9.0 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H).

실시예 7. 4-(2,5-디플루오르페닐)-2,2-디메틸-5-(4-메틸티오페닐)-3(Example 7. 4- (2,5-difluorophenyl) -2,2-dimethyl-5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 7의2-(2,5-디플루오르페닐)-1-(4-메틸티오페닐)에탄온 6g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 실시하여 표제 화합물 2.48g(33.2%)을 얻었다.2- (2,5-difluorophenyl) -1- (4-methylthiophenyl) ethane of Preparative Example 7 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone 2.48 g (33.2%) of the title compound were obtained by the same method as the method A of Example 1, except that 6 g of ON was used.

m.p.: 90.5~91℃m.p .: 90.5 ~ 91 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.56(s, 6H), 2.49(s, 3H), 7.01-7.06(m, 3H), 7.17(d,J=8.7Hz, 2H), 7.53(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.56 (s, 6H), 2.49 (s, 3H), 7.01-7.06 (m, 3H), 7.17 (d, J = 8.7 Hz, 2H), 7.53 (d , J = 8.4 Hz, 2H)

실시예 8. 4-(3,5-디플루오르페닐)-2,2-디메틸-5-(4-메틸티오페닐)-3(Example 8. 4- (3,5-difluorophenyl) -2,2-dimethyl-5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 8의2-(3,5-디플루오르페닐)-1-(4-메틸티오페닐)에탄온 5.32g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 실시하여 표제 화합물 3.21g(48.5%)을 얻었다.2- (3,5-difluorophenyl) -1- (4-methylthiophenyl) ethane of Preparative Example 8 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone 3.21 g (48.5%) of the title compound were obtained by the same method as the method A of Example 1, except that 5.32 g of ON was used.

m.p.: 122~123℃m.p .: 122 ~ 123 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.51(s, 3H), 6.71-6.78(m, 1H), 6.84-6.92(m, 2H), 7.21(d,J=8.7Hz, 2H), 7.55(d,J=9.0Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.51 (s, 3H), 6.71-6.78 (m, 1H), 6.84-6.92 (m, 2H), 7.21 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 9.0 Hz, 2H)

실시예 9. 2,2-디메틸-5-(4-메틸티오페닐)-4-(2-티에닐)-3(Example 9. 2,2-dimethyl-5- (4-methylthiophenyl) -4- (2-thienyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 9의1-(4-메틸티오페닐)-2-(2-싸이에닐)에탄온 140mg을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 실시하여 표제 화합물 27.1mg(15.2%)을 얻었다.140 mg of 1- (4-methylthiophenyl) -2- (2-thienyl) ethanone of Preparative Example 9 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone 27.1 mg (15.2%) of the title compound were obtained by the same method as the method A of Example 1 except for using.

m.p.: 113~114℃m.p .: 113 ~ 114 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.51(s, 3H), 7.05(dd,J=5.1, 3.9Hz, 2H), 7.11(dd,J=3.6, 1.2Hz, 1H), 7.22(d,J=8.4Hz, 2H), 7.33(dd,J=5.1Hz, 1H), 7.68(d,J=9.0Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.51 (s, 3H), 7.05 (dd, J = 5.1, 3.9 Hz, 2H), 7.11 (dd, J = 3.6, 1.2 Hz , 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.33 (dd, J = 5.1 Hz, 1H), 7.68 (d, J = 9.0 Hz, 2H)

실시예 10. 2,2-디메틸-4-메틸-5-(4-메틸티오페닐)-3(Example 10. 2,2-dimethyl-4-methyl-5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 1g 대신에 예비제조예 10의1-(4-메틸티오페닐)프로판온 1g을 사용한다는 것을 제외하고는 실시예 1의 방법 B와 동일한 방법으로 실시하여 표제 화합물 0.91g(66.1%)을 얻었다.Example 1, except that 1 g of 1- (4-methylthiophenyl) propanone of Preparative Example 10 is used instead of 1 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone. 0.91 g (66.1%) of the title compound were obtained by the same method as the method B.

m.p.: 140~141℃m.p .: 140 ~ 141 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.45(s, 6H), 1.99(s, 3H), 2.54(s, 3H), 7.34(d,J=8.4Hz, 2H), 7.75(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.45 (s, 6H), 1.99 (s, 3H), 2.54 (s, 3H), 7.34 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H)

실시예 11. 2,2-디메틸-4-이소프로필-5-(4-메틸티오페닐)-3(Example 11. 2,2-dimethyl-4-isopropyl-5- (4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 1g 대신에 예비제조예 11의 4-메틸-1-(4-메틸티오페닐)펜탄온 1g을 사용한다는 것을 제외하고 실시예 1의 방법 B와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 102mg(7.7%)을 얻었다.Except for using 1 g of 4-methyl-1- (4-methylthiophenyl) pentanone of Preparative Example 11 instead of 1 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone. After reacting in the same manner as in Method B of Example 1, the pure portion was separated by column chromatography (ethyl acetate: hexane = 1: 6) to obtain 102 mg (7.7%) of the title compound.

1H-NMR(CDCl3, 300MHz, δ) 1.29(d, J=6.9Hz, 6H), 1.41(s, 6H), 2.91(sept, J=6.9Hz, 1H), 7.32(d,J=8.7Hz, 2H), 7.58(d,J=8.4Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.29 (d, J = 6.9 Hz, 6H), 1.41 (s, 6H), 2.91 (sept, J = 6.9 Hz, 1H), 7.32 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H)

실시예 12. 2,2-디메틸-4,5-디페닐-3(Example 12. 2,2-dimethyl-4,5-diphenyl-3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 데옥시벤조인 200mg을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 176mg(65.0%)을 제조하였다.The reaction was carried out in the same manner as in Method A of Example 1, except that 200 mg of deoxybenzoin was used instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone, followed by a column Chromatography (ethyl acetate: hexane = 1: 6) separated the pure portion to prepare 176 mg (65.0%) of the title compound.

1H-NMR(CDCl3, 300MHz, δ) 1.54(s, 6H), 7.13(d,J=8.4Hz, 2H), 7.24-7.37(m, 6H), 7.58(d,J=8.7Hz, 2H). 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.54 (s, 6H), 7.13 (d, J = 8.4 Hz, 2H), 7.24-7.37 (m, 6H), 7.58 (d, J = 8.7 Hz, 2H ).

실시예 13. 4-(2-클로로페닐)-5-(3-플루오르-4-메틸티오페닐)-2,2-디메틸-3(Example 13. 4- (2-chlorophenyl) -5- (3-fluoro-4-methylthiophenyl) -2,2-dimethyl-3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 12의 2-(2-클로로페닐)-1-(3-플루오르-4-메틸티오페닐)에탄온 1.0g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 726mg(59.0%)을 얻었다.2- (2-chlorophenyl) -1- (3-fluoro-4-methylthiophenyl) of Preparative Example 12 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone The reaction was carried out in the same manner as in Method A of Example 1, except that 1.0 g of ethanone was used, and then the pure portion was separated by column chromatography (ethyl acetate: hexane = 1: 6) to give 726 mg (59.0%) of the title compound. )

1H-NMR(CDCl3, 300MHz, δ) 1.58(s, 6H), 2.46(s, 3H), 7.10(m, 1H), 7.26(m, 3H), 7.34(m, 2H), 7.49(m, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.58 (s, 6H), 2.46 (s, 3H), 7.10 (m, 1H), 7.26 (m, 3H), 7.34 (m, 2H), 7.49 (m , 1H)

실시예 14. 2,2-디메틸-5-(2-플루오르-4-메틸티오페닐)-4-(3-플루오르페닐)-3(Example 14. 2,2-Dimethyl-5- (2-fluoro-4-methylthiophenyl) -4- (3-fluorophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 13의 1-(2-플루오르-4-메틸티오페닐)-2-(3-플루오르페닐)에탄온 615mg을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 487mg(63.6%)을 얻었다.1- (2-fluoro-4-methylthiophenyl) -2- (3-fluorophenyl) of Preparative Example 13 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone The reaction was carried out in the same manner as in Method A of Example 1, except that 615 mg of ethanone was used, and then the pure portion was separated by column chromatography (ethyl acetate: hexane = 1: 6) to give 487 mg (63.6%) of the title compound. Got.

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.51(s, 3H), 6.94(m, 4H), 7.06(m, 1H), 7.26(m, 1H), 7.43(m, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.51 (s, 3H), 6.94 (m, 4H), 7.06 (m, 1H), 7.26 (m, 1H), 7.43 (m , 1H)

실시예 15. 5-(3-브로모-4-메틸티오페닐)-4-(2,5-디플루오르페닐)-2,2-디메틸-3(Example 15. 5- (3-Bromo-4-methylthiophenyl) -4- (2,5-difluorophenyl) -2,2-dimethyl-3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 14의 1-(3-브로모-4-메틸티오페닐)-2-(2,5-디플루오르페닐)에탄온 2.31g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 1.22g(44.4%)을 얻었다.1- (3-bromo-4-methylthiophenyl) -2- (2,5- of Preparative Example 14 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone The reaction was carried out in the same manner as in Method A of Example 1, except that 2.31 g of difluorophenyl) ethanone was used, and then the pure portion was separated by column chromatography (ethyl acetate: hexane = 1: 6) to obtain the title compound. 1.22 g (44.4%) were obtained.

1H-NMR(CDCl3, 300MHz, δ) 1.57(s, 6H), 2.47(s, 3H), 7.04(m, 4H), 7.44(dd,J=8.7, 1.8Hz 2H), 7.86(d,J=1.5Hz, 1H), 8.09(m, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.57 (s, 6H), 2.47 (s, 3H), 7.04 (m, 4H), 7.44 (dd, J = 8.7, 1.8 Hz 2H), 7.86 (d, J = 1.5 Hz, 1H), 8.09 (m, 1H)

실시예 16. 5-(3-클로로-4-메틸티오페닐)-2,2-디메틸-4-(3-플루오르페닐)-3(Example 16. 5- (3-Chloro-4-methylthiophenyl) -2,2-dimethyl-4- (3-fluorophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 15의 1-(3-클로로-4-메틸티오페닐)-2-(3-플루오르페닐)에탄온 2.80g을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 2.98g(86.5%)을 얻었다.1- (3-chloro-4-methylthiophenyl) -2- (3-fluorophenyl) of Preparative Example 15 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone The reaction was carried out in the same manner as in Method A of Example 1, except that 2.80 g of ethanone was used, and then 2.98 g (86.5) of the title compound was separated by column chromatography (ethyl acetate: hexane = 1: 6). %) Was obtained.

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.49(s, 3H), 7.05(m, 3H), 7.06(d,J=8.1Hz, 1H), 7.34(m, 1H), 7.44(dd,J=8.4, 1.8Hz, 1H), 7.69(d,J=1.8Hz, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.49 (s, 3H), 7.05 (m, 3H), 7.06 (d, J = 8.1 Hz, 1H), 7.34 (m, 1H ), 7.44 (dd, J = 8.4, 1.8 Hz, 1H), 7.69 (d, J = 1.8 Hz, 1H)

실시예 17. 2,2-디메틸-4-(3,5-디플루오르페닐)-5-(3-메틸-4-메틸티오페닐)-3(Example 17. 2,2-dimethyl-4- (3,5-difluorophenyl) -5- (3-methyl-4-methylthiophenyl) -3 ( 2H2H )-퓨라논) -Furanone

2-(3-플루오르페닐)-1-(4-메틸티오페닐)에탄온 100g 대신에 예비제조예 16의 2-(3,5-디플루오르페닐)-1-(3-메틸-4-메틸티오페닐)에탄온 530mg을 사용한다는 것을 제외하고는 실시예 1의 방법 A와 동일한 방법으로 반응시킨 다음, 컬럼크로마토그라피(에틸아세테이트:헥산=1:6)로 순수한 부분을 분리하여 표제 화합물 427mg(65.3%)을 얻었다.2- (3,5-difluorophenyl) -1- (3-methyl-4-methyl of Preparative Example 16 instead of 100 g of 2- (3-fluorophenyl) -1- (4-methylthiophenyl) ethanone The reaction was carried out in the same manner as in Method A of Example 1, except that 530 mg of thiophenyl) ethanone was used, and then the pure portion was separated by column chromatography (ethyl acetate: hexane = 1: 6) to give 427 mg of the title compound. 65.3%).

1H-NMR(CDCl3, 300MHz, δ) 1.55(s, 6H), 2.29(s, 3H), 2.50(s, 3H), 6.74(m, 1H), 6.89(m, 2H), 7.08(d,J=8.1Hz, 1H), 7.41(dd,J=8.4, 2.1Hz, 1H), 7.45(d,J=1.5Hz, 1H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.55 (s, 6H), 2.29 (s, 3H), 2.50 (s, 3H), 6.74 (m, 1H), 6.89 (m, 2H), 7.08 (d , J = 8.1 Hz, 1H), 7.41 (dd, J = 8.4, 2.1 Hz, 1H), 7.45 (d, J = 1.5 Hz, 1H)

실시예 18. 2,2-디메틸-4-(3-플루오르페닐)-5-(4-메틸술포닐페닐)-3(Example 18. 2,2-dimethyl-4- (3-fluorophenyl) -5- (4-methylsulfonylphenyl) -3 ( 2H2H )-퓨라논) -Furanone

[방법 A][Method A]

2-(3-플루오르페닐)-1-(4-메틸술포닐페닐)에탄온 1g을 테트라하이드로퓨란 10㎖에 녹인 다음, 빙수욕에서 소디움하이드라이드(95%) 0.23g을 적가하였다. 이를 상온에서 1시간 동안 교반한 다음, 다시 빙수욕에서 냉각하였다. 여기에 2-브로모이소부티릴시아나이드 0.64g을 적가한 후, 7시간 동안 상온에서 교반하고, 소량의 정제수를 가한 뒤 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 100㎖에 녹이고 정제수와 소금수로 세척하였다. 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 에틸아세테이트-헥산에서 결정화하여 표제 화합물 0.75g(60.8%)을 얻었다.1 g of 2- (3-fluorophenyl) -1- (4-methylsulfonylphenyl) ethanone was dissolved in 10 ml of tetrahydrofuran, and then 0.23 g of sodium hydride (95%) was added dropwise in an ice water bath. It was stirred at room temperature for 1 hour and then cooled again in an ice-water bath. 0.64 g of 2-bromoisobutyryl cyanide was added dropwise thereto, stirred at room temperature for 7 hours, and a small amount of purified water was added thereto, followed by concentration under reduced pressure. The obtained residue was dissolved in 100 ml of ethyl acetate and washed with purified water and brine. Anhydrous magnesium sulfate was added and dried. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in ethyl acetate-hexane to give 0.75 g (60.8%) of the title compound.

m.p.: 178~179℃m.p .: 178 ~ 179 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.58(s, 6H), 3.08(s, 3H), 7.05(m, 3H), 7.33(m, 1H), 7.83(d,J=8.7Hz, 2H), 7.95(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.58 (s, 6H), 3.08 (s, 3H), 7.05 (m, 3H), 7.33 (m, 1H), 7.83 (d, J = 8.7 Hz, 2H ), 7.95 (d, J = 8.7 Hz, 2H)

[방법 B][Method B]

디에틸에테르 50㎖에 녹인 디이소프로필아민 0.92㎖에 에틸마그네슘브로마이드 5.76㎖(1M/Et2O)을 -70℃에서 적가하고, 상온에서 1시간 동안 교반하였다. -70℃로 냉각한 뒤 테트라하이드로퓨란 20㎖에 녹인 2-(3-플루오르페닐)-1-(4-메틸술포닐페닐)에탄온 1g을 적가한 뒤 반응온도를 상온으로 서서히 올리며 1시간 동안 교반하였다. 빙수욕에서 2-브로모이소부티릴브로마이드 1.06g을 적가하고, 2시간 동안 상온에서 교반하였다. 반응액을 정제수로 세척하고 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 테트라하이드로퓨란 50㎖에 녹이고, 소디움하이드라이드(95%) 0.18g을 적가하였다. 상온에서 2시간 동안 교반한 뒤, 반응액에 소량의 정제수를 가하고, 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 100㎖에 녹여 정제수와 소금수로 세척하고, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 에틸아세테이트-헥산에서 결정화하여 표제 화합물 0.57g(46.2%)을 얻었다.5.76 mL (1 M / Et 2 O) of ethylmagnesium bromide was added dropwise at −70 ° C. to 0.92 mL of diisopropylamine dissolved in 50 mL of diethyl ether, followed by stirring at room temperature for 1 hour. After cooling to -70 ° C, 1 g of 2- (3-fluorophenyl) -1- (4-methylsulfonylphenyl) ethanone dissolved in 20 ml of tetrahydrofuran was added dropwise, and the reaction temperature was gradually raised to room temperature for 1 hour. Stirred. 1.06 g of 2-bromoisobutyryl bromide was added dropwise in an ice water bath, and stirred at room temperature for 2 hours. The reaction solution was washed with purified water and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in 50 ml of tetrahydrofuran, and 0.18 g of sodium hydride (95%) was added dropwise. After stirring for 2 hours at room temperature, a small amount of purified water was added to the reaction solution, and concentrated under reduced pressure. The obtained residue was dissolved in 100 ml of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in ethyl acetate-hexane to give 0.57 g (46.2%) of the title compound.

[방법 C][Method C]

4-(3-플루오르페닐)-2,2-디메틸-5-(메틸티오페닐)-3(2H)-퓨라논 3.03g을 테트라하이드퓨란/메탄올/정제수 50㎖/50㎖/50㎖에 녹였다. 상온에서 옥손(OXONE) 10g을 가하고 2시간 동안 교반하였다. 반응액을 감압 농축하고, 메틸렌클로라이드 150㎖로 추출한 다음, 유기층을 소금수로 세척하고, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 메틸렌클로라이드-헥산에서 결정화하여 표제 화합물 3.3g(99.2%)을 얻었다.3.03 g of 4- (3-fluorophenyl) -2,2-dimethyl-5- (methylthiophenyl) -3 ( 2H ) -furanone was dissolved in 50 mL / 50 mL / 50 mL of tetrahydrofuran / methanol / purified water. . 10 g of OXONE was added at room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, extracted with 150 ml of methylene chloride, the organic layer was washed with brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in methylene chloride-hexane to give 3.3 g (99.2%) of the title compound.

실시예 19. 2,2-디메틸-4-(3-클로로페닐)-5-(4-메틸술피닐페닐)-3(Example 19. 2,2-dimethyl-4- (3-chlorophenyl) -5- (4-methylsulfinylphenyl) -3 ( 2H2H )-퓨라논) -Furanone

[방법 A][Method A]

2-(3-클로로페닐)-1-(4-메틸술피닐페닐)에탄온 1.14g을 테트라하이드로퓨란 20㎖에 녹인 다음, -20℃에서 소디움하이드라이드(95%) 0.32g을 적가하고, 상온에서 1시간 동안 교반한 후, 다시 빙수욕에서 냉각하였다. 여기에 2-브로모이소부티릴시아나이드 0.87g을 적가하고, 5시간 동안 상온에서 교반한 후, 반응액에 소량의정제수를 가한 뒤 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 100㎖에 녹이고 정제수와 소금수로 세척한 후, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 에틸아세테이트-헥산에서 결정화하여 표제 화합물 0.76g(56.6%)을 얻었다.1.14 g of 2- (3-chlorophenyl) -1- (4-methylsulfinylphenyl) ethanone was dissolved in 20 ml of tetrahydrofuran, and 0.32 g of sodium hydride (95%) was added dropwise at -20 ° C, After stirring for 1 hour at room temperature, the mixture was cooled again in an ice-water bath. 0.87 g of 2-bromoisobutyryl cyanide was added dropwise thereto, stirred at room temperature for 5 hours, and then a small amount of purified water was added to the reaction solution, followed by concentration under reduced pressure. The obtained residue was dissolved in 100 ml of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in ethyl acetate-hexane to give 0.76 g (56.6%) of the title compound.

m.p.: 109~111℃m.p .: 109 ~ 111 ℃

1H-NMR(CDCl3, 300MHz, δ) 1.57(s, 6H), 2.75(s, 3H), 7.17(m, 1H), 7.31(m, 2H), 7.65(d,J=8.4Hz, 2H), 7.80(d,J=8.7Hz, 2H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 1.57 (s, 6H), 2.75 (s, 3H), 7.17 (m, 1H), 7.31 (m, 2H), 7.65 (d, J = 8.4 Hz, 2H ), 7.80 (d, J = 8.7 Hz, 2H)

[방법 B][Method B]

4-(3-클로로페닐)-2,2-디메틸-5-(메틸티오페닐)-3(2H)-퓨라논 10.98g을 메틸렌클로라이드 250㎖에 녹였다. 빙수욕에서 메틸렌클로라이드 150㎖에 녹인 m-클로로퍼옥시벤조산 6.59g을 적가하였다. 반응액을 포화 NaHCO3수용액과 소금수로 세척하고, 무수 황산마그네슘을 가하여 건조한 후, 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 컬럼 크로마토그라피(에틸아세테이트:헥산=2:1)를 하여 순수한 부분을 얻은 뒤, 에틸아세테이트-헥산에서 결정화하여 표제 화합물 6.33g(55.1%)을 얻었다.10.98 g of 4- (3-chlorophenyl) -2,2-dimethyl-5- (methylthiophenyl) -3 ( 2H ) -furanone was dissolved in 250 ml of methylene chloride. 6.59 g of m-chloroperoxybenzoic acid dissolved in 150 ml of methylene chloride in an ice water bath was added dropwise. The reaction solution was washed with saturated aqueous NaHCO 3 solution and brine, dried over anhydrous magnesium sulfate, and then the insolubles were filtered and the filtrate was concentrated under reduced pressure. The residue thus obtained was purified by column chromatography (ethyl acetate: hexane = 2: 1) to obtain a pure part, which was then crystallized in ethyl acetate-hexane to give 6.33 g (55.1%) of the title compound.

비교예 1. 1,2-디페닐바이닐 2-브로모-2-메틸프로피오네이트Comparative Example 1. 1,2-diphenylvinyl 2-bromo-2-methylpropionate

데옥시벤조인 500mg을 테트라하이드로퓨란 10㎖에 녹인 다음, 빙수욕에서 소디움하이드라이드(95%) 193mg을 적가하였다. 상온에서 1시간 동안 교반하고, 다시 빙수욕에서 냉각한 다음, 여기에 2-브로모이소부티릴브로마이드 700mg을 적가하였다. 그 다음, 5시간 동안 상온에서 교반하고, 반응액에 소량의 정제수를 가한 뒤 감압 농축하였다. 얻어진 잔사를 에틸아세테이트 30㎖에 녹이고 정제수와 소금수로 세척한 후, 무수 황산마그네슘을 가하여 건조하였다. 불용물을 여과하고, 여액을 감압 농축하였다. 얻어진 잔사를 에틸아세테이트-헥산에서 결정화하여 표제 화합물 659mg(74.9%)을 얻었다.500 mg of deoxybenzoin was dissolved in 10 ml of tetrahydrofuran, and then 193 mg of sodium hydride (95%) was added dropwise in an ice water bath. After stirring for 1 hour at room temperature, cooled again in an ice-water bath, 700 mg of 2-bromoisobutyryl bromide was added dropwise thereto. Then, the mixture was stirred at room temperature for 5 hours, and a small amount of purified water was added to the reaction solution, followed by concentration under reduced pressure. The obtained residue was dissolved in 30 ml of ethyl acetate, washed with purified water and brine, and dried over anhydrous magnesium sulfate. Insolubles were filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized in ethyl acetate-hexane to give 659 mg (74.9%) of the title compound.

m.p.: 42~44℃m.p .: 42 ~ 44 ℃

1H-NMR(CDCl3, 300MHz, δ) 2.01(s, 6H), 6.73(s, 1H), 7.27-7.62(m, 10H) 1 H-NMR (CDCl 3 , 300 MHz, δ) 2.01 (s, 6H), 6.73 (s, 1H), 7.27-7.62 (m, 10H)

이상에서 설명한 바와 같이, 본 발명의 제조 방법은 선택적인 C-아실레이션 반응을 유도하여 축합, 고리화 반응을 동시에 진행시켜 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체, 특히 4,5-디아릴-3(2H)-퓨라논 유도체를 높은 수율로 제조하는데 매우 효과적이다.As described above, the preparation method of the present invention induces a selective C-acylation reaction and simultaneously proceeds the condensation and cyclization reactions to a 2,2,4,5-quarried substituted 3 ( 2H ) -furanone derivative. In particular, 4,5-diaryl-3 ( 2H ) -furanone derivatives are very effective in producing high yields.

Claims (8)

하기 일반식 (Ⅱ)의 화합물을 2-할로이소부티릴시아나이드 또는 2-할로이소부티릴할라이드와 반응시켜 하기 일반식(Ⅰ)의 2,2,4,5-사중 치환된 3(2H)-퓨라논[2,2,4,5-tetrasubstituted 3(2H)-furanone] 유도체를 수득하고,The compound of the following general formula (II) is reacted with 2-haloisobutyryl cyanide or 2-haloisobutyryl halide to make 2,2,4,5-quadruple 3 ( 2H ) of the general formula (I) -Furanone [2,2,4,5-tetrasubstituted 3 ( 2H ) -furanone] derivative is obtained, 필요에 따라 산화제의 존재하에 산화반응을 수행함을 특징으로 하는 하기 일반식 (Ⅰ)의 2,2,4,5-사중 치환된 3(2H)-퓨라논 유도체의 제조 방법.A process for the preparation of 2,2,4,5-quadically substituted 3 ( 2H ) -furanone derivatives of the general formula (I), which is carried out in the presence of an oxidizing agent if necessary. [화학식 1][Formula 1] [화학식 3][Formula 3] 상기 식에서,Where X는 치환되거나 치환되지 않은 아릴 또는 헤테로 아릴기이고,X is a substituted or unsubstituted aryl or hetero aryl group, Y는 알킬, 싸이클로알킬, 치환되거나 치환되지 않은 아릴 또는 헤테로 아릴기이다.Y is an alkyl, cycloalkyl, substituted or unsubstituted aryl or hetero aryl group. 제 1항에 있어서, 상기 일반식(Ⅱ)의 화합물과 2-할로이소부티릴시아나이드또는 2-할로이소부티릴할라이드의 반응은 유기용매중에서 염기의 존재하에 수행함을 특징으로 하는 제조방법.The process according to claim 1, wherein the reaction of the compound of formula (II) with 2-haloisobutyryl cyanide or 2-haloisobutyryl halide is carried out in the presence of a base in an organic solvent. 제 1항 또는 제 2항에 있어서,The method according to claim 1 or 2, X는 페닐기, 또는X is a phenyl group, or 할로겐, 탄소수 1 내지 5의 알킬, 탄소수 1 내지 5의 할로알킬, 탄소수 1 내지 5의 알콕시, 니트로, 탄소수 1 내지 3의 알킬티오, 탄소수 1 내지 3의 알킬술포닐 또는 탄소수 1 내지 3의 알킬술피닐기가 치환된 페닐기이고,Halogen, alkyl of 1 to 5 carbon atoms, haloalkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, nitro, alkylthio of 1 to 3 carbon atoms, alkylsulfonyl of 1 to 3 carbon atoms, or alkyl of 1 to 3 carbon atoms The pinyl group is a substituted phenyl group, Y는 탄소수 1 내지 6의 알킬, 티에닐, 페닐기, 또는Y is alkyl having 1 to 6 carbon atoms, thienyl, phenyl group, or 할로겐, 탄소수 1 내지 5의 알킬, 탄소수 1 내지 5의 할로알킬, 탄소수 1 내지 5의 알콕시, 니트로, 탄소수 1 내지 3의 알킬티오, 탄소수 1 내지 3의 알킬술포닐 또는 탄소수 1 내지 3의 알킬술피닐기가 치환된 페닐기임을 특징으로 하는 제조방법.Halogen, alkyl of 1 to 5 carbon atoms, haloalkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, nitro, alkylthio of 1 to 3 carbon atoms, alkylsulfonyl of 1 to 3 carbon atoms, or alkyl of 1 to 3 carbon atoms A manufacturing method characterized in that the pinyl group is a substituted phenyl group. 제 1항 내지 제 3항 중 어느 한 항에 있어서, 2-할로이소부티릴시아나이드는 2-브로모이소부티릴시아나이드 또는 2-클로로이소부티릴시아나이드이고, 2-할로이소부티릴할라이드는 2-브로모이소부티릴브로마이드, 2-브로모이소부티릴클로라이드, 2-클로로이소부티릴브로마이드 또는 2-클로로이소부티릴클로라이드임을 특징으로 하는 제조 방법.The 2-haloisobutyryl cyanide of any one of claims 1 to 3 is 2-bromoisobutyryl cyanide or 2-chloroisobutyryl cyanide, and 2-haloisobutyryl halide. Is 2-bromoisobutyryl bromide, 2-bromoisobutyryl chloride, 2-chloroisobutyryl bromide or 2-chloroisobutyryl chloride. 제 2항에 있어서, 염기는 소디움하이드라이드, 부틸리튬, 리튬t-부톡사이드, 포타시움t-부톡사이드, 소디움t-부톡사이드, 리튬디이소프로필아마이드, 소디움비스(트리메틸실릴)아마이드, 포타시움비스(트리메틸실릴)아마이드, 리튬비스(트리메틸실릴)아마이드 또는 브로모마그네슘디이소프로필아마이드임을 특징으로 하는 제조 방법.The method of claim 2, wherein the base is sodium hydride, butyllithium, lithium t -butoxide, potassium t -butoxide, sodium t -butoxide, lithium diisopropylamide, sodium bis (trimethylsilyl) amide, potassium bis ( Trimethylsilyl) amide, lithium bis (trimethylsilyl) amide or bromo magnesium diisopropylamide. 제 2항에 있어서, 유기 용매는 디메틸포름아마이드, 디메틸설폭사이드, 디메틸에테르, 디이소프로필에테르, 디부틸에테르, 테트라하이드로퓨란, 디옥산, 1,2-디메톡시에탄, 벤젠, 톨루엔 또는 자일렌임을 특징으로 하는 제조 방법The organic solvent according to claim 2, wherein the organic solvent is dimethylformamide, dimethyl sulfoxide, dimethyl ether, diisopropyl ether, dibutyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, benzene, toluene or xylene Manufacturing method characterized by 제 1항 내지 제 3항 중 어느 한 항에 있어서, 산화제는m-클로로퍼옥시벤조산, 퍼옥시벤조산, 옥손, 소디움퍼카보네이트(Na2CO3-1.5H2O2) 또는 과산화수소수임을 특징으로 하는 제조 방법.The oxidizing agent according to any one of claims 1 to 3, wherein the oxidizing agent is m -chloroperoxybenzoic acid, peroxybenzoic acid, oxone, sodium percarbonate (Na 2 CO 3 -1.5H 2 O 2 ), or hydrogen peroxide. Manufacturing method. 제 1항 내지 제 3항 중 어느 한 항에 있어서, 상기 산화반응에 의해 일반식 (Ⅰ)중 X 또는 Y의 아릴 치환기가 알킬티오기인 화합물이 알킬술피닐 또는 알킬술포닐기를 가진 화합물로 전환됨을 특징으로 하는 제조 방법.The compound according to any one of claims 1 to 3, wherein, by the oxidation reaction, a compound in which the aryl substituent of X or Y in the general formula (I) is an alkylthio group is converted into a compound having an alkylsulfinyl or alkylsulfonyl group. A manufacturing method characterized by the above-mentioned.
KR1020000016866A 1999-04-14 2000-03-31 Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives KR20010094519A (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
KR1020000016866A KR20010094519A (en) 2000-03-31 2000-03-31 Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives
CZ20013662A CZ300766B6 (en) 1999-04-14 2000-04-12 4,5-Diaryl-3(2H)-furanone derivatives, process of their preparation and use
PT00921133T PT1109799E (en) 1999-04-14 2000-04-12 4,5-DIARYL-3 (2H) -FURANONE DERIVATIVES AS CICLOOXYGENASE-2 INHIBITORS
AT00921133T ATE256672T1 (en) 1999-04-14 2000-04-12 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS
NZ514101A NZ514101A (en) 1999-04-14 2000-04-12 4,5-diaryl-3( 2H )-furanone derivatives as cyclooxygenase-2 inhibitors
PL351125A PL204249B1 (en) 1999-04-14 2000-04-12 Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
US09/744,762 US6492416B1 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors
SK1451-2001A SK286314B6 (en) 1999-04-14 2000-04-12 4,5-Diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors
CNB008062293A CN1166658C (en) 1999-04-14 2000-04-12 4,5-diaryl-3(i(2H))-furanone derivatives as cyclooxygenase-2 inhibitors
AU41480/00A AU767811B2 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors
EA200100958A EA004432B1 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
DE60007267T DE60007267T2 (en) 1999-04-14 2000-04-12 4,5-DIARYL-3 (2H) FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS
CA002369979A CA2369979C (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
TR2001/02958T TR200102958T2 (en) 1999-04-14 2000-04-12 4,5-diaryl-3 (2H) -furanone derivatives as cyclooxygenase-2 inhibitors.
IL14530500A IL145305A0 (en) 1999-04-14 2000-04-12 4,5-diaryl-3 (2h)-furanone derivatives as cyclooxygenase-2 inhibitors
HU0200623A HU227863B1 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
KR1020017012902A KR20010111584A (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
PCT/KR2000/000339 WO2000061571A1 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
DZ003265A DZ3265A1 (en) 1999-04-14 2000-04-12 4,5-DIARYL-3 (2H) -FURANONE DERIVATIVES AS CYCLO-OXYGENASE-2 INHIBITORS
ES00921133T ES2213007T3 (en) 1999-04-14 2000-04-12 DERIVATIVES OF 4,5-DIARIL-3 (2H) -FURANONE AS INHIBITORS OF CYCLLOXYGENASA-2.
BRPI0011172A BRPI0011172B8 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
JP2000610845A JP3844657B2 (en) 1999-04-14 2000-04-12 4,5-Diaryl-3 (2H) -furanone derivatives as cyclooxygenase-2 inhibitors
EP00921133A EP1109799B1 (en) 1999-04-14 2000-04-12 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
IL145305A IL145305A (en) 1999-04-14 2001-09-06 4,5 - diaryl - 3 (2h) - furanone derivatives as cyclooxygenase - 2 inhibitors
MA26357A MA25406A1 (en) 1999-04-14 2001-10-12 4,5-DIARYL -3 (2H) -FURANONE DERIVATIVES FOR USE AS CYCLOOXYGENASE-2 INHIBITORS
NO20014986A NO327814B1 (en) 1999-04-14 2001-10-12 4,5-diaryl-3 (2H) -furanone derivatives, processes for their preparation, pharmaceutical preparations and use of such derivatives
MXPA01010312A MXPA01010312A (en) 1999-04-14 2001-10-12 4,5-diaryl-3(2h.
HK02108027.8A HK1046413B (en) 1999-04-14 2002-11-05 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000016866A KR20010094519A (en) 2000-03-31 2000-03-31 Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives

Publications (1)

Publication Number Publication Date
KR20010094519A true KR20010094519A (en) 2001-11-01

Family

ID=19660647

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000016866A KR20010094519A (en) 1999-04-14 2000-03-31 Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives

Country Status (1)

Country Link
KR (1) KR20010094519A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0119908B1 (en) * 1994-04-18 1997-10-30 강박광 3(2h)-furanone derivatives
WO1999012917A1 (en) * 1997-09-05 1999-03-18 Roche Diagnostics Gmbh Ureido and thioureido derivatives of 4-amino-2(5h)-furanones and 4-amino-2(5h)-thiophenones as antitumor agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0119908B1 (en) * 1994-04-18 1997-10-30 강박광 3(2h)-furanone derivatives
WO1999012917A1 (en) * 1997-09-05 1999-03-18 Roche Diagnostics Gmbh Ureido and thioureido derivatives of 4-amino-2(5h)-furanones and 4-amino-2(5h)-thiophenones as antitumor agents

Similar Documents

Publication Publication Date Title
JP5162598B2 (en) Process for producing 2-substituted-5- (1-alkylthio) alkylpyrimidine
HU219464B (en) Ethinyl substituted chroman and thiochroman derivatives and method for producing
KR960001913B1 (en) Process for the preparation of 3-cyano-4-aryl-pyrroles
KR20010094519A (en) Synthetic Method of 2,2,4,5-tetrasubstituted 3(2H)-furanone derivatives
US4094886A (en) Process for producing allyl alcohol derivatives useful in prostaglandin synthesis
US5523319A (en) Compounds of the benzo-heterocycle family
JP4020141B2 (en) Method for producing 1-acetoxy-3- (substituted phenyl) propene compound
EP1735297B1 (en) Synthesising method and benzoxathiepine intermediates
Deshpande et al. Simple syntheses of (+)-orthosporin and (−)-semivioxanthin methyl ether
WO2004043942A1 (en) Process for producing ϝ-jasmolactone
Garcı́a et al. Highly stereoselective hydrocyanation of optically pure α-sulfinylaldehydes
FR2475035A1 (en) 2,6,6-TRIMETHYL-CYCLOHEX-3-ENE-1-ONE, APPLICATION TO THE PRODUCTION OF BETA-DAMASCENONE
JP4123709B2 (en) Preparation of aromatic acrylonitrile derivatives
KR20090085173A (en) New alkyl aryl selenide derivatives and process for preparing thereof
Ruano et al. Asymmetric synthesis of tertiary vinyl carbinols by highly stereoselective methylation of α-methyl-β-ketosulfoxides with aluminum reagents
JPH0245614B2 (en)
JP4162891B2 (en) Method for producing tetrahydrothiophene derivative
JPH06211833A (en) Production of 1,3-dioxane-4,6-dione derivative
JPWO2005058859A1 (en) Process for producing 3- (4-tetrahydropyranyl) -3-oxopropanoic acid alkyl compound and 4-acyltetrahydropyran
US5786515A (en) Synthesis of α-chloro or fluoro ketones
FI75336B (en) ANVAENDNING AV -HYDROXYKETONACETALER.
JPH0272166A (en) Optically active oxiranes
JPH01153648A (en) Production of aryltrifluoromethylacetylene
JPS6165877A (en) Hydroxylactone
FR2863613A1 (en) New 3-substituted hydroxy-phenylboronic acid derivatives, useful in synthesis of non-steroidal Vitamin D3 analogs by Suzuki coupling to trifluoromethylsulfonyloxy-benzene derivative

Legal Events

Date Code Title Description
A201 Request for examination